Neoadjuvant cemiplimab in patients (pts) with stage II-IV (M0) cutaneous squamous cell carcinoma (CSCC): Primary analysis of a phase II study

被引：0
作者：
Gross, N. [1 ]
Miller, D. M. [2 ]
Khushanlani, N. [3 ]
Divi, V. [4 ]
Ruiz, E. S. [5 ]
Lipson, E. J. [6 ]
Meier, F. [7 ]
Su, Y. B. [8 ]
Swiecicki, P. L. [9 ]
Atlas, J. L. [10 ]
Geiger, J. L. [11 ]
Hauschild, A. [12 ]
Choe, J. H. [13 ]
Hughes, B. G. M. [14 ]
Yoo, S-Y. [15 ]
Fenech, K. [15 ]
Mathias, M. D. [15 ]
Han, H. [15 ]
Fury, M. G. [15 ]
Rischin, D. [16 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Head & Neck Surg, Houston, TX USA
[2] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA USA
[3] H Lee Moffitt Canc Ctr Res Inst, Dept Cutaneous Oncol, Magnolia Campus, Tampa, FL USA
[4] Stanford Canc Inst, Dept Otolaryngol Head & Neck Surg, Palo Alto, CA USA
[5] Harvard Med Sch, Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA
[6] Johns Hopkins Med, Oncol Dept, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[7] Univ Hosp Carl Gustav Carus, Dept Dermatol, Dresden, Germany
[8] Nebraska Canc Specialists, Head & Neck Med Oncol, Omaha, NE USA
[9] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[10] Atrium Hlth, Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA
[11] Cleveland Clin, Solid Tumor Oncol, Sandusky, OH USA
[12] UK SH, Dept Dermatol, Campus Kiel, Kiel, Germany
[13] Duke Canc Inst, Oncol, Durham, NC USA
[14] Royal Brisbane & Womens Hosp, Canc Care Serv, Herston, Qld, Australia
[15] Regeneron Pharmaceut Inc, Clin Sci, Tarrytown, NY USA
[16] Peter MacCallum Canc Ctr, Med Oncol Dept, Melbourne, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.915
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
789O
引用
收藏
页码：S904 / S905
页数：2
相关论文
共 50 条
  • [1] Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
    Gross, N.
    Ferrarotto, R.
    Nagarajan, P.
    Bell, D.
    El-Naggar, A.
    Johnson, J. M.
    Yuan, Y.
    Glisson, B. S.
    Wong, M.
    Rosenthal, D.
    Esmaeli, B.
    Migden, M. R.
    Wargo, J.
    Weber, R. S.
    Myers, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 910 - 910
  • [2] A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up
    Gross, N.
    Miller, D. M.
    Khushalani, N. I.
    Divi, V.
    Ruiz, E.
    Lipson, E. J.
    Meier, F.
    Su, Y. B.
    Swiecicki, P. L.
    Atlas, J. L.
    Geiger, J. L.
    Hauschild, A.
    Choe, J. H.
    Hughes, B. G. M.
    Yoo, S. Y.
    Mathias, M. D.
    Han, H.
    Fury, M. G.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S655 - S655
  • [3] Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
    Gross, N. D.
    Miller, D. M.
    Khushalani, N., I
    Divi, V
    Ruiz, E. S.
    Meier, F.
    Su, Y. B.
    Swiecicki, P. L.
    Atlas, J.
    Geiger, J. L.
    Hauschild, A.
    Choe, J. H.
    Hughes, B. G. M.
    Schadendorf, D.
    Patel, V. A.
    Homsi, J.
    Taube, J. M.
    Lim, A. M.
    Ferrarotto, R.
    Kaufman, H. L.
    Seebach, F.
    Lowy, I
    Yoo, S-Y
    Mathias, M.
    Fenech, K.
    Han, H.
    Fury, M. G.
    Rischin, D.
    Lipson, E. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (17) : 1557 - 1568
  • [4] Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.
    Rischin, Danny
    Khushalani, Nikhil I.
    Schmults, Chrysalyne D.
    Guminski, Alexander David
    Chang, Anne Lynn S.
    Lewis, Karl D.
    Lim, Annette May Ling
    Hernandez-Aya, Leonel Fernando
    Hughes, Brett Gordon Maxwell
    Schadendorf, Dirk
    Hauschild, Axel
    Stankevich, Elizabeth
    Booth, Jocelyn
    Li, Siyu
    Chen, Zhen
    Okoye, Emmanuel
    Lowy, Israel
    Fury, Matthew G.
    Migden, Michael Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Neoadjuvant chemotherapy with continuous infusion of cisplatin and fluorouracil in stage II-IV, M0 squamous cell carcinoma of the head and neck
    Boni, C
    Moretti, G
    Savoldi, L
    Armaroli, L
    Barbieri, W
    Bisagni, G
    Caroggio, A
    Lotti, C
    Pedroni, C
    Manenti, AL
    Rondini, E
    Sassi, M
    Zadro, A
    TUMORI, 1996, 82 (06) : 567 - 572
  • [6] Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results
    Rischin, D.
    Hughes, B. G. M.
    Basset-Seguin, N.
    Schadendorf, D.
    Bowyer, S.
    Trabelsi, S.
    Meier, F.
    Eigentler, T.
    Echarren, V. Casado
    Migden, M. R.
    Hauschild, A.
    Schmults, C. D.
    Yoo, S-Y.
    Paccaly, A.
    Jankovic, V.
    Seebach, F.
    Drutman, S.
    Booth, J.
    Fury, M. G.
    Guminski, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S886 - S887
  • [7] Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
    Gross, Neil
    Miller, David M.
    Khushalani, Nikhil, I
    Divi, Vasu
    Ruiz, Emily S.
    Lipson, Evan J.
    Meier, Friedegund
    Su, Yungpo Bernard
    Swiecicki, Paul L.
    Atlas, Jennifer
    Geiger, Jessica L.
    Hauschild, Axel
    Choe, Jennifer H.
    Hughes, Brett G. M.
    Schadendorf, Dirk
    Patel, Vishal A.
    Homsi, Jade
    Taube, Janis M.
    Lim, Annette M.
    Ferrarotto, Renata
    Yoo, Suk-Young
    Mathias, Melissa
    Han, Hyunsil
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew G.
    Rischin, Danny
    LANCET ONCOLOGY, 2023, 24 (11) : 1196 - 1205
  • [8] NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma
    Ascierto, Paolo Antonio
    Bossi, Paolo
    Mandala, Mario
    Queirolo, Paola
    Spagnolo, Francesco
    Bassetto, Franco
    Rampinelli, Vittorio
    Giovacchini, Francesco
    Pennacchioli, Elisabetta
    Caraco, Corrado
    Parrinello, Gianpiero
    Mallardo, Domenico
    Giannarelli, Diana
    Trojaniello, Claudia
    Massi, Daniela
    Chiarion-Sileni, Vanna
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3
    Migden, M. R.
    Schmults, C.
    Khushanlani, N.
    Guminski, A.
    Chang, A. L.
    Lewis, K.
    Ansstas, G.
    Bowyer, S. E.
    Hughes, B. G. M.
    Schadendorf, D.
    Modi, B.
    Dunn, L.
    Flatz, L.
    Hauschild, A.
    Yoo, S-Y.
    Booth, J.
    Seebach, F.
    Lowy, I.
    Fury, M. G.
    Rischin, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S918 - S919
  • [10] Pembrolizumab in patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC): The phase II KEYNOTE-629 study
    Licitra, L. F.
    Siu, L. L.
    Cohen, E. E. W.
    Zhang, P.
    Gumuscu, B.
    Swaby, R.
    Harrington, K.
    ANNALS OF ONCOLOGY, 2018, 29
12345